Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$5.00 +5.7%	$6.59	$4.15 ▼ $17.42	$53.36M	0.72	53,066 shs	46,279 shs
KPTI Karyopharm Therapeutics	$6.35 +4.6%	$5.80	$3.51 ▼ $18.00	$54.42M	0.58	82,489 shs	51,875 shs
NXTC NextCure	$0.49 +6.1%	$0.54	$0.22 ▼ $1.82	$13.83M	0.89	102,350 shs	169,723 shs
PMVP PMV Pharmaceuticals	$1.00	$1.14	$0.82 ▼ $2.26	$51.93M	1.49	250,611 shs	47,232 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-1.05%	+7.26%	-44.09%	-41.17%	-70.33%
KPTI Karyopharm Therapeutics	+8.01%	+12.41%	+45.91%	-40.66%	-61.82%
NXTC NextCure	+1.04%	+25.96%	-7.04%	-41.84%	-65.57%
PMVP PMV Pharmaceuticals	-3.85%	-9.09%	-9.91%	-29.08%	-42.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.854 of 5 stars	4.4	5.0	0.0	1.8	1.7	1.3
KPTI Karyopharm Therapeutics	3.526 of 5 stars	3.5	0.0	4.6	1.1	2.5	0.6
NXTC NextCure	4.6501 of 5 stars	3.5	5.0	4.3	3.6	1.7	1.3
PMVP PMV Pharmaceuticals	2.2741 of 5 stars	3.6	2.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.83	Moderate Buy	$33.00	560.00% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$57.50	805.51% Upside
NXTC NextCure	3.00	Buy	$3.50	609.65% Upside
PMVP PMV Pharmaceuticals	3.25	Buy	$5.67	466.67% Upside

Current Analyst Ratings Breakdown

Latest NXTC, KPTI, PMVP, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00
3/20/2025	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/17/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
3/7/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $3.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00
2/28/2025	AVTX Avalo Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$48.00
2/26/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $56.00
2/21/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$18.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$441K	121.00	N/A	N/A	$9.11 per share	0.55
KPTI Karyopharm Therapeutics	$145.24M	0.37	N/A	N/A	($1.47) per share	-4.32
NXTC NextCure	N/A	N/A	N/A	N/A	$4.10 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$4.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	5/12/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$15.29	N/A	N/A	N/A	-52.62%	N/A	-39.58%	5/6/2025 (Estimated)
NXTC NextCure	-$62.72M	-$1.98	N/A	N/A	N/A	N/A	-62.50%	-53.67%	5/1/2025 (Estimated)
PMVP PMV Pharmaceuticals	-$68.96M	-$1.14	N/A	N/A	N/A	N/A	-24.20%	-21.67%	5/8/2025 (Estimated)

Latest NXTC, KPTI, PMVP, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	N/A	N/A	N/A	$35.12 million	N/A
5/12/2025	Q4 2024	AVTX Avalo Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	PMVP PMV Pharmaceuticals	-$0.37	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	NXTC NextCure	-$0.40	N/A	N/A	N/A	N/A	N/A
3/6/2025	Q4 2024	NXTC NextCure	-$0.34	-$0.41	-$0.07	-$0.41	N/A	N/A
3/3/2025	Q4 2024	PMVP PMV Pharmaceuticals	-$0.37	-$0.45	-$0.08	-$0.45	N/A	N/A
2/19/2025	Q4 2024	KPTI Karyopharm Therapeutics	-$3.90	-$3.60	+$0.30	-$0.24	$30.29 million	$30.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	1.42	1.42
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
NXTC NextCure	N/A	9.07	9.07
PMVP PMV Pharmaceuticals	N/A	13.98	13.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
KPTI Karyopharm Therapeutics	66.44%
NXTC NextCure	42.65%
PMVP PMV Pharmaceuticals	90.20%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
KPTI Karyopharm Therapeutics	2.75%
NXTC NextCure	13.30%
PMVP PMV Pharmaceuticals	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.67 million	10.37 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.57 million	122.72 million	Optionable
NXTC NextCure	90	28.05 million	24.28 million	Optionable
PMVP PMV Pharmaceuticals	50	51.93 million	47.81 million	Optionable

NXTC, KPTI, PMVP, and AVTX Headlines

Recent News About These Companies

PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% - Should You Sell?

April 28 at 2:32 AM | marketbeat.com

PMV Pharmaceuticals (NASDAQ:PMVP) Shares Down 3.7% - Time to Sell?

April 26 at 2:37 AM | americanbankingnews.com

Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Up 7.83%

April 21, 2025 | aaii.com

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing

March 5, 2025 | zacks.com

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)

March 3, 2025 | markets.businessinsider.com

PMV Pharmaceuticals sees cash runway to end of 2026

March 3, 2025 | markets.businessinsider.com

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

March 3, 2025 | globenewswire.com

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

February 11, 2025 | globenewswire.com

PMV Pharmaceuticals stock hits 52-week low at $1.32

January 21, 2025 | msn.com

PMV Pharmaceuticals files $200M mixed securities shelf

November 22, 2024 | markets.businessinsider.com

PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

November 9, 2024 | markets.businessinsider.com

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 7, 2024 | markets.businessinsider.com

PMV Pharmaceuticals (PMVP) Gets a Buy from Craig-Hallum

October 25, 2024 | markets.businessinsider.com

Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)

October 25, 2024 | markets.businessinsider.com

PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial

October 23, 2024 | finance.yahoo.com

PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial

October 23, 2024 | markets.businessinsider.com

PMV Pharma (NASDAQ:PMVP) Stock Quotes, Forecast and News Summary

October 8, 2024 | benzinga.com

Penny Stocks To Buy With Just $1500: PMVP, BOLD, SPRO

September 28, 2024 | msn.com

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Insider Sells $10,827.00 in Stock

September 13, 2024 | insidertrades.com

PMV Pharmaceuticals Inc (PMVP) Stock: Understanding Its Underlying Value

August 28, 2024 | bovnews.com

Pmv Pharmaceuticals Inc (PMVP)

August 20, 2024 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, KPTI, PMVP, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$5.00 +0.27 (+5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$5.01 +0.01 (+0.22%)

As of 07:50 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Karyopharm Therapeutics NASDAQ:KPTI

$6.35 +0.28 (+4.61%)

Closing price 04:00 PM Eastern

Extended Trading

$6.36 +0.01 (+0.22%)

As of 07:17 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NextCure NASDAQ:NXTC

$0.49 +0.03 (+6.11%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 +0.03 (+5.43%)

As of 07:58 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

PMV Pharmaceuticals NASDAQ:PMVP

$1.00 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 0.00 (-0.10%)

As of 04:05 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time